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Abstract
Periconceptional supplementation could extend the period over which maternal and fetal nutrition is improved,
but there are many challenges facing early-life intervention studies. Periconceptional trials differ from pregnancy
supplementation trials, not only because of the very early or pre-gestational timing of nutrient exposure but also
because they generate subsidiary information on participants who remain non-pregnant. The methodological
challenges are more complex although, if well designed, they provide opportunities to evaluate concurrent
hypotheses related to the health of non-pregnant women, especially nulliparous adolescents. This review examines
the framework of published and ongoing randomised trial designs. Four cohorts typically arise from the
periconceptional trial design — two of which are non-pregnant and two are pregnant — and this structure
provides assessment options related to pre-pregnant, maternal, pregnancy and fetal outcomes. Conceptually the
initial decision for single or micronutrient intervention is central — as is the choice of dosage and content — in
order to establish a comparative framework across trials, improve standardisation, and facilitate interpretation of
mechanistic hypotheses. Other trial features considered in the review include: measurement options for baseline
and outcome assessments; adherence to long-term supplementation; sample size considerations in relation to
duration of nutrient supplementation; cohort size for non-pregnant and pregnant cohorts as the latter is influenced
by parity selection; integrating qualitative studies and data management issues. Emphasis is given to low resource
settings where high infection rates and the possibility of nutrient-infection interactions may require appropriate
safety monitoring. The focus is on pragmatic issues that may help investigators planning a periconceptional trial.
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Background
Trials of periconceptional folic acid supplementation to
reduce neural tube defects [1, 2] and of iodised oil ad-
ministered early in pregnancy to avoid cretinism [3]
identified the major influence on clinical outcomes of
maternal nutritional status during the first trimester of
pregnancy. Since these early studies, many trials have
been conducted, mostly with second and third trimester
nutrient supplementation [4]. The majority have
compared iron plus folic acid supplementation with in-
terventions using variable compositions of micronutri-
ents and vitamins. Meta-analyses and systematic reviews
of clinical outcomes have reported varied results, from
null effects on neonatal mortality [5] to improvement in
general health indicators such as birth weight. Most
showed no differences in the risk of pre-term birth, still-
birth, maternal or neonatal outcomes [6], with conflict-
ing results for infant mortality reductions [7]. Null
effects [8] or varied findings were reported for fetal
growth restriction [8, 9]. Importantly, an increased risk
of neonatal death was reported with multimicronutrient
compared with iron/folate interventions after the first
trimester of pregnancy [6, 10]. The evidence to support
daily iron and folate supplementation in pregnancy is
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based mainly on its beneficial effects on maternal an-
aemia [11, 12], with micronutrients providing no add-
itional benefit on third trimester maternal anaemia
compared with iron-folic acid alone [9, 13].
None of the above trials started with mechanistic hy-
potheses. Improved understanding of nutritional inter-
mediate pathways could explain differences between
trials in fetal and pregnancy outcomes, but this requires
integrated placental and biomarker studies and infection
profiling from early in gestation [14]. Critical nutritional
periods in early pregnancy include the pre-embryonic
and embryonic developmental stages. If a nutrient ex-
posure during these periods is associated either posi-
tively or negatively with the postulated clinical outcome,
a causal pathway is implicated. Periconceptional trials
re-focus attention on the fetal growth effects of placental
vascularisation and function and the mechanisms deter-
mining fetal and placental phenotypes [15, 16]. Recently
described effects of maternal overweight on cardiometa-
bolic disease risk in the offspring on later adult disease
indicate that early gestational nutritional influences can
have lifelong effects [17]. Given that the periconcep-
tional use of nutrition supplements has been assessed in
few controlled trials [18], their mechanistic basis is even
less evident.
In view of the potential importance of pre-pregnancy
supplementation, this paper outlines several aspects re-
lated to the framework of periconceptional supplementa-
tion trials, including: underlying mechanistic hypotheses;
single and multimicronutrient supplementation as alter-
native trial interventions; sample size considerations in
relation to duration of nutrient supplementation, cohort
size and composition; outcome measurement options
and characteristics; design options, with comparison of
published and current study designs, outcome assess-
ments and supplement adherence; the role of qualitative
studies within trial designs and data management op-
tions. Without improved insights into the nature and
conduct of these studies there is a risk that they will
yield confusing results. Statistical issues specific to data
analysis are not included in the review, as these are trial
specific.
The main emphasis is on developing countries where
nutritional deficiencies are common and adolescents
give birth while still growing [19]. Trying to improve nu-
trition before the first pregnancy is attractive, especially
if this helps to optimise nutrient requirements through-
out pregnancy.
Review
Methods
We identified published studies using PubMed and
Scopus search engines and the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL; The Cochrane
Library). Search terms included micronutrient supple-
ments, periconceptional period, placentation, embryo-
genesis, pregnancy outcomes, birth weight, growth
restriction, iron, folic acid, and micronutrients. For iden-
tification of randomised controlled trials or prospective
cohort studies we identified human studies on pericon-
ceptional interventions with nutrition supplements cov-
ering the period 1950 to July 2015 with no language
restriction. Information from recent meta-analyses and
systematic reviews addressing the periconceptional
period, pre-conception, or pre-pregnancy nutrient sup-
plement interventions was reviewed. Ongoing rando-
mised trials with published or available methodologies
but still awaiting trial closure were included. Observa-
tional studies were excluded, unless population based, as
these may be confounded by baseline differences in the
prevalence of one or more nutrient deficiencies. Figure 1
shows the PRISMA flow diagram, and Table 1 lists the
study inclusion and exclusion parameters. Animal stud-
ies to identify biological mechanisms for nutritional
regulation of fetal growth and gestational length were
reviewed to identify mechanistic hypotheses.
As definition of the periconceptional period varied
across studies, here it has been defined as taking supple-
ments before, or at the time of, the last menstrual period
prior to conception, and up until the end of the first tri-
mester. Overall quality of evidence for outcomes was
not graded, as the purpose of this review was to assess
methodological frameworks, and not the quality of the
evidence for a particular outcome. For the majority of
cohort studies published, grading schemes for quality of
evidence had previously been applied [6].
Results and discussion
Trial structures and outcome assessments
Figure 2 illustrates a schema for 17 periconceptional stud-
ies identified for this review. Nine studies were double
blind randomised trials [20–28], two unblinded rando-
mised trials [29, 30], and six community- or population-
based unblinded prospective studies [29, 31–34, 36]. Six
randomised trials had two cohorts [20, 21, 24, 25, 30, 31],
and five trials three or four cohorts [22, 23, 26, 28, 29].
Three included untreated controls [22, 23, 29], and four
received placebo [20, 25, 27, 32] and the remainder a con-
trol intervention [21, 24, 26, 30]. All the community- or
population-based studies defined two study arms [33–37],
with one using four study arms [38]. Five included un-
treated control groups [34–38]. They covered 24 countries
with the earliest randomised trial reported in 1981 [20].
The study sample sizes in Fig. 2 refer to numbers at
enrolment. Studies with two intervention arms in sin-
gle country locations are listed first, followed by trials
with three or four intervention arms or with multiple
country locations. Three were in sub-Saharan Africa
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Fig. 1 PRISMA flow diagram
Table 1 Study inclusion and exclusion parameters
Study inclusion parameters Study exclusion parameters
- Human studies from 1950 to July 2015, with no language restriction - Studies with nutrient interventions commencing during, but not
before pregnancy
- Blinded and unblinded randomised trials - If time of intervention was unclear
- Community-/population-based studies - Poorly defined control or comparison groups
- Ongoing randomised trials studies with published methodologies, but
awaiting trial closure
- Observational human studies
- Clear definition of nutrient intervention
- Indication of period of periconceptional supplementation
- Definition of outcome variables (maternal, fetal, or infant outcomes).
- Studies in non-pregnant women prior to ascertainment of pregnancy
- Starting early in first trimester up to 28 days after last menstrual period
- Individually randomised or population-based studies
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Fig. 2 Summary outlines of periconceptional nutrition supplement intervention studies. Description of intervention supplements uses
investigators’ terminology. Multimicronutrient contents of intervention supplements summarised in Table 3. All intervention regimens are daily
unless specified. Regimen details, blinding and duration are outlined in Table 8. Hb: haemoglobin; NTDs: neural tube defects; IDA: iron deficiency
anaemia; PTB: pre-term birth; LBW: low birth weight; SB: stillbirth; HC: head circumference; Brackets: reference number
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[21, 29, 31], five in Europe [20, 22, 23, 30, 37], eight
in Asia [24–26, 28, 29, 33–35], with single locations
in Cuba [36], Algeria [38], Guatemala, Australia,
Canada, Israel and Russia [23]. The minimum period
of pre-pregnancy supplementation was 28 days or one
month, and the maximum 3.5 years, with the majority
providing pre-pregnancy supplementation for a period
less than nine months. All studies supplemented
through the first trimester; one randomised trial con-
tinued supplementation in one arm through later tri-
mesters [29], and another trial continued
supplementation after an intervening pregnancy [28].
For non-pregnant cohorts in the randomised trials, that
is, study subjects who did not become pregnant during the
study period, six trials reported no outcome measurements
and no end assessment survey [20, 22, 23, 25, 26, 30], five
reported haemoglobin [24, 26, 27, 29, 30], three provided
iron biomarker measurements [21, 26, 29], one measured
anthropometry, morbidity, risk of malaria and lower genital
tract infections, haemoglobin and iron biomarkers [21],
and one measured maternal mortality [28]. All the com-
munity-/population-based studies had no end assessment
for participants who remained non-pregnant, except one
study which measured iron deficiency anaemia [33]. Those
without a non-pregnant evaluation were primarily asses-
sing neural tube defect prevention and did not anticipate
side effects with the use of folate supplements. Four studies
reported neural tube defects alone [20, 22, 34, 36], five re-
ported birth weight measurement and neural tube defects
or birth defects [20, 22, 34, 36, 37], twelve included birth
weight outcomes [21, 25, 26, 28–30, 33–38] and variably
measured gestational age [21, 26, 29, 35, 37], neonatal an-
thropometry [25, 29, 37], and maternal and neonatal iodine
status [38]. Only two trials included tissue placental sam-
pling [21, 29] or placental function [27, 29]. Consent was a
single process except for one study which took consent at
each key stage: enrolment, first pregnancy visit and for a
follow-up infant survey [21].
Trial design
Figure 3 provides a structural outline for a periconcep-
tional intervention trial using individual randomisation
at enrolment to intervention or non-intervention arms.
This template illustrates that four cohorts arise from a
periconceptional design, two non-pregnant and two
pregnant.
In terms of trial inclusion criteria, the pregnancy rate
will be optimised if only women who have experienced
menarche are selected. Exclusions at enrolment generally
include currently pregnant women and those with sig-
nificant illnesses. In low resource settings, moderately
severe anaemia (Hb < 10 g/dl) may be a criterion for ex-
clusion. Enrolment of anaemic women avoids selection
bias but creates a heterogenous cohort, as those with
nutritional anaemias may benefit more from supplemen-
tation than non-anaemic women, with different outcome
effects. Women with anaemia observed at baseline
would normally require treatment with iron and folate
supplements. This might compromise study outcomes if
large numbers had to be treated, especially in developing
countries where two-thirds of women are typically an-
aemic. Treatment is sometimes reserved for severe an-
aemia, providing adequate follow-up of the less anaemic
participants is possible. An alternative would be treat-
ing participants with clinical anaemia and without
haemoglobin assessment. Sera collected at baseline
could be stored for ethically approved retrospective
measurement of nutritional biomarkers. Outcome as-
sessments would then be based on differences in
mean haemoglobin values at follow-up, precluding
comparison of change from baseline haemoglobin
concentration [39]. For the studies outlined in Fig. 2,
eleven collected no baseline blood sample for haemo-
globin [21–23, 25, 28, 30, 32, 34–37], and one indi-
cated clinical screening for anaemia, with baseline
sera storage, and exclusion only if hospital treatment
was required [21]. Of the remaining studies, five mea-
sured baseline haemoglobin [24, 26, 29, 31, 33], two
excluded participants if this was <7 g/dl [24, 26], one
if <8 g/dl [29], one treated if <7 g/dl and re-recruited
[31], and one did not describe study practice [33].
Comprehensive baseline assessment is central for
assessing the magnitude of change in outcome measures
[39]. Ideally this would include dietary studies, as the ef-
fect of the supplement has to be distinguished from a
non-specific effect of diet [20]. Other confounding fac-
tors or biases such as maternal mental health or work-
load activities [26] may generate associations between
exposure at baseline and the outcome and need to be
pre-specified if anticipated, or indicated as post hoc ex-
ploratory analyses [40].
In terms of monitoring visits, Fig. 3 does not specify fre-
quency for the non-pregnant and pregnant cohorts, as this
is governed by the timing of supplement delivery (daily,
weekly, monthly), method(s) of adherence assessment and
the frequency of safety assessments. A weekly structure
was employed in the PALUFER trial of weekly iron and
folate supplementation because it addressed safety issues
which required weekly follow-up visits [21]. The intensity
of follow-up may itself influence adherence.
The non-pregnant cohort
In periconceptional studies, the trial design generally fo-
cusses on the pregnancy cohort and pregnancy-related
primary outcomes. However, the evaluation of the non-
pregnant cohort is important, as secondary outcomes,
such as anaemia, specific nutritional deficiencies, or in-
flammatory or biomarker profiles can be measured and
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compared with the pregnant cohort. For studies includ-
ing parous women, parity-related hypotheses can be
evaluated such as effects of supplementation on fertility
in different parity cohorts [41], growth in nulliparous
adolescent women [19], or predictive value of nutritional
parameters at baseline for outcomes at the end assess-
ment [42]. This requires collecting relevant anthropo-
metric and nutritional data.
Non-pregnant women may perceive less benefit from
supplement use before pregnancy, and adherence levels
in periconceptional trials may differ from pregnancy
supplementation studies starting after the first trimester
[24]. Follow-up of the non-pregnant cohort after discon-
tinuation of supplementation may be indicated if latency
in onset of adverse events might occur (for example,
with delayed incidence of infection) or if pregnancy is
probable soon after cessation. Monitoring unscheduled
health visits is useful, as it may reflect adverse events or
relate directly to trial outcomes.
Figure 3 includes an interim cross-sectional survey
which can provide an interim safety analysis for trials
with infection parameters as primary outcomes, or if
there is a substantial concern about side effects. An in-
terim survey needs to be carefully designed, especially if
treatment is required which may influence outcomes.
An interim survey may not be required if there is a long
lag between recruitment and availability of the primary
outcome at birth (for example, birth size) [29].
The pregnant cohort
Identification of conception can be based on a reported
missed menstrual period with confirmation by a preg-
nancy test. Some pregnant participants might still be
excluded, dependent on whether a minimal period of non-
pregnant supplementation was pre-specified. Trial re-
entry for participants with repeat pregnancy during the
period of supplementation would normally be an
Fig. 3 Periconceptional trial structure showing parallel cohorts of pregnant and non-pregnant women. First antenatal (AN) attendance is scheduled at
the end of the first trimester. The second and third AN attendances would correspond with the second and third trimesters. LTFU is loss to follow-up.
It may be appropriate to complete a separate cross-sectional survey in the non-pregnant cohort, at a selected follow-up time, if interim
safety assessments are required, as for example, in the Burkina Faso trial [21]. Visit frequency in the pregnant cohort is governed by operational issues
as well as study hypotheses
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exclusion criterion as the two pregnancies would not be
independent, or if only nulliparous women were eligible.
In the majority of studies in this review, trial supple-
mentation continued through early gestation to a sched-
uled first or early second trimester visit. For practical
reasons this first scheduled study visit could correspond
with the first visit for routine antenatal care when an
ultrasound assessment can also confirm gestational age.
This visit may be used as an end-point if parameters
early in gestation are related to the primary outcome.
After the first antenatal study assessment, and depend-
ing on study objectives, the intervention supplement
may be stopped in order to allow the pregnancy cohorts
in both arms to receive standard antenatal iron and fol-
ate supplementation, possibly in higher doses than in
the intervention supplement, and following national
guidelines. If study outcomes are measured at delivery,
then re-consenting the individual to pregnancy follow-
up should be considered as part of Good Clinical Prac-
tice (GCP), especially as there are two distinct cohorts
(pregnant and non-pregnant) in the study design. The
same applies to any further infant follow-up.
The frequency of study visits during pregnancy may
vary according to biological or obstetric outcomes to be
measured, although at least one further antenatal at-
tendance prior to delivery would be appropriate for
monitoring purposes. Assessment at 32–34 weeks gesta-
tion may be the most practical, as it provides near-
delivery clinical indicators (for example, infection sta-
tus, anaemia, blood pressure) which can be used as
proxy measures if assessment at delivery may be missed,
as is often the case with village deliveries in developing
countries. Monitoring of unscheduled pregnancy visits
may be required to pick up pregnancy complications or
intervening treatments. Adherence to routine antenatal
iron and folate supplements can be assessed from the
antenatal card or using monthly tablet counts. Frequent
monitoring may lead to study fatigue, which may be re-
duced by assistance with transport and free health care
provision, providing these are not provided as active
inducements.
At delivery, clinical outcomes are assessed as part of
standard care, but because of the importance of placental
assessment in periconceptional interventions, it is a prior-
ity to obtain adequate placental tissue, with chorioamnio-
tic membrane samples. Processing for placental histology
may have specific requirements, for example, malaria
histopathology [43]. Placental weight should be measured
after trimming of the cord and marginal membranes.
At delivery, duplicate anthropometric measurements
reduce measurement error of infant length, which can
be measured as crown-heel and crown-rump length, to-
gether with the baby’s head and abdominal circumfer-
ences. In addition to newborn examination, a clinical
gestational age assessment is advantageous, especially if
pregnancy ultrasound assessments are not routine. The
time of cord clamping should be established, as this in-
fluences anaemia risk in infancy [44], although this
might be difficult for babies delivered at home by trad-
itional birth attendants. Post-partum outcomes would
require a scheduled study visit in the first week, with an
additional postnatal visit at 4–6 weeks.
The infant cohort
Only three of the seventeen periconceptional studies
reviewed included infant follow-up assessments, two of
which adopted a cohort design [23, 29], and one a cross-
sectional survey assessment [21]. There is an issue about
statistical power if these outcomes are being measured
opportunistically, and in analysis, inadequate power re-
duces the impact of any negative findings. If powered,
large cohorts may be required and multiple statistical
comparisons will need to be addressed.
The importance of infant follow-up relates to predict-
ive risk of infant micronutrient status on infection risk
and assessment of potential benefits to the offspring
[45]. The operational framework for infant follow-up
should be established early in the study, as infants can
be born within seven months of enrolment or sooner if
participants are already pregnant at recruitment. Infant
follow-up will require active household visits and/or
linkage with routine postnatal care and child health
care visits. Infant assessments at 6 weeks, 3, 6, and
9 months and at one year of age would be appropriate
for screening for anaemia, vaccination status and infec-
tion profiles, with less frequent scheduling in the sec-
ond year. The timing of these would vary according to
the outcomes of interest, but an assessment survey at
around 9–12 months of age would be suitable as infant
haemoglobin would normally plateau by that time.
This timing would facilitate initial developmental and
auditory testing, infant feeding practices and assess-
ment of core breast feeding indicators. An alternative,
more pragmatic, but less informative approach for
assessing infant outcomes would be to complete a sin-
gle cross-sectional survey for all study infants after
the last trial infant is born. The mean age of children
in this survey would be expected to be comparable
by trial arm, unless the intervention had influenced
child survival.
Generating mechanistic hypotheses as a trial basis
Mechanisms can be considered in a general classification
related to maternal, placental or fetal factors. These will
interface, and underlying hypotheses should consider
this interaction. Information from human, animal or la-
boratory studies should be considered. Table 2 summa-
rises putative mechanisms using the above classification.
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General mechanisms
These may not account for compensatory growth mecha-
nisms, such as the placenta adapting by up-regulating its
transfer systems, and some changes may be irreversible,
such as altered expression of transcription factors which
in turn produce reduced cell content and enzyme actrivity
[46]. Cell cycle regulation and cytoskeletal remodelling are
critical processes in the nutritional programming of
embryonic development [47], and rapid fetal growth may
increase vulnerability to impaired nutrient supply [48].
Even a minor variation in maternal nutritional status is
capable of producing important shifts in the fetal environ-
ment, as demonstrated in animal studies [49]. There is
also evidence that nutrient status in the immediate pre-
conception period may affect fertility [41, 50].
Specific mechanisms
The possibility of sex differences in studies concerned
with birth size should be considered because of sex differ-
entials in growth [51], sex-specific effects of first trimester
progesterone levels on female birth weight [52], and sex-
specific epigenetic effects [53]. A number of nutrient- and
endocrine-related mechanisms are listed in Table 2, in-
cluding interfacing hormone receptors on the placenta
and fetal-hypothalamic axis [51, 54–57]. Although all trials
include surveillance for adverse events, there may be a
basis for evaluating hypotheses related to adverse events
[58]. An example would be when potential nutrient-
Table 2 Maternal, placental and fetal mechanistic hypotheses
Maternal (biochemical, endocrine factors, and plasma volume)
- Glucocorticoid effects on the fetal hypothalamic-adrenal axis (see fetal
effects) [54, 82]
- Glucose homeostasis on metabolic responses leading to greater fetal
fat deposition, insulin secretion, DNA methylation, and differential
development of fetal endocrine systems [51, 55]
- Specific mineral deficiencies and impaired metabolic pathways [82]
- Limited macronutrients required for fetal growth [82]
- Adiposity [83]
- Oxidative stress associated with deficiencies of specific micronutrient
antioxidant activities [84]
- Infection with transcriptional inflammatory response through IL-6
receptor alpha and prostaglandin response leads to cervical ripening
and uterine contractions [85]
- Homocysteine metabolic effects on obstetrical vascular disease or
placental spiral artery function [86]
- Interferon tau and progesterone effects on selective nutrient transport
to the uterine lumen, with cell signalling pathways effecting,
migration, and protein synthesis in trophectoderm [64]
- Urinary metabolites measured at the end of the first trimester and
increased risk of negative birth outcomes [87]
- Biochemical markers of early placentation and downstream resistance
to uterine arterial flow [77]
- Sex-specific effects of first trimester progesterone levels [52]
Placental (growth, morphology, vascularisation and function)
- Placental oxygen consumption is greater than fetal, and anaemia and
placental hypoxia lead to free radical production, alteration in
placental size, and vascularisation [15, 88–90]
- Alterations of number and surface area of arterioles in tertiary villi, and
factors controlling endothelial re-modelling and trophoblast cell
turnover from immature villi to conductance villi and gas exchanging
terminal villi [16]
- Impaired molecular signalling networks [91]
- Reduced transfer capacity due to impaired utero-placental flow and
fetal nutrient uptake [92]
- Impairment of fetal trophoblast and angiogenesis due to oxidative
stress and inflammation [15, 93, 94]
- Long-chain polyunsaturated fatty effects on placental weight and
surface area of gas exchanging placental capillaries [89, 95]
- Iron associated with markers of vasculopathy and placental growth
factor excess [96]
- Alterations in placental phenotype and availability of placental
hormone receptors and effects of hormones on the morphology,
transport capacity and endocrine function of the placenta [56]
- Decreased nitric oxide bioavailability through low dietary arginine
substrate and antioxidant supply [82]
- Interference with folate homeostasis in malaria infected placentae [97]
Fetal (embryonic, fetal growth factors and endocrine axes)
- Periconceptional undernutrition accelerating fetal hypothalamic-
pituitary-adrenal (HPA) axis activation [54], mediated by different
influences of maternal glucocorticoid on maturation of the fetal HPA
axis, via placental 11-beta-hydroxysteroid dehydrogenase isozymes.
Fetal exposure to glucose, fatty acids, and micronutrients, with
resultant increased fetal insulin secretion, could influence development
of the HPA axis controlling infant appetite [57]
Table 2 Maternal, placental and fetal mechanistic hypotheses
(Continued)
- Placental metabolic alterations associated with the growth restricted
fetus [89]
- Pre-term birth frequency in the growth restricted fetus [98]
- Altered fragility of chorioamniotic membrane [99]
- Inadequate micronutrient supply [48]
- One-carbon metabolic effects on methyl groups and DNA
methylation [100]
- Fetal epigenomic effects during early stages of embryogenesis leading
to stable and inheritable alterations in genes through covalent
modifications of DNA and gatekeeper genes leading to nutritional
programming [53, 101]
- Transport effects on methionine from the mother to the coelomic
cavity and amniotic fluid [64]
- Vitamin independent effect of homocysteine in the fetal metabolic
cycle [64]
- Thyroid hormone effects of mild/moderate iodine deficiency on
cognitive ability and growth [102]
- Fetal angiogenic and placental growth factors affecting newborn
thyroid function [103]
- Association of rapidly growing fetus with increased vulnerability to
impaired nutrient supply [104, 105]
- Influence on development and activation of regulatory T cells in the
human fetus [106]
Brabin et al. Trials  (2016) 17:58 Page 11 of 24
infection interactions suggest negative outcomes for some
participants. One periconceptional trial measured malaria
risk in early gestation in participants randomised to re-
ceive weekly iron and folate supplements, or folate alone
[21]. The hypothesis was that Plasmodium falciparum
parasites utilise iron for growth [45, 59].
Selection of single versus multimicronutrient
interventions
While there is consensus on use of folic acid in the peri-
conceptional period for prevention of neural tube defects,
opinions vary on whether to use single micronutrient sup-
plementation, or composite multimicronutrients including
the nutrient of interest [10]. In low resource settings the
rationale for multimicronutrient supplementation is influ-
enced by high population prevalence of chronic undernu-
trition in pregnancy, and a broad nutritional approach is
pragmatic. In such settings a single micronutrient supple-
ment may be less likely to improve placental function and
fetal growth. Conversely, in areas where overnutrition is
common, the developmental origins of health and disease
hypothesis suggests that fetal exposure to additional
glucose, fatty acids and micronutrients may increase
fetal insulin secretion, influencing the development of
the hypothalamic-endocrine system, which controls
appetite [60, 61].
The rationale for the composition of mineral and vita-
min multimicronutrient supplements is often unclear.
Individual nutrient dosage is often based on dietary rec-
ommendations using physiological requirements, but
there are substantive differences between trials. Table 3
illustrates this variation in composition for the seventeen
reviewed studies. Five used folic acid alone, and were de-
signed to assess efficacy for prevention of neural tube
Table 3 Nutrient content of vitamins and micronutrients used in supplementation trials outlined in Fig. 2
Trial country
[reference]
Ca
mg
Cu
mg
Folic
acid
mg
I
μg
Fe
mg
Mg
mg
Mn
mg
Niacin
mg
P
mg
K
mg
Se
μg
Zn
mg
Biotin
μg
Vitamins
B1
mg
B2
mg
A
μg
B12
μg
C
mg
D
IU
E
mg
K
μg
B5
mg
B6
mg
Wales [20] - - 4 - - - - - - - - - - - - - - - - - - - -
Gambia
[27, 31]
- 2 0.4 150 30 - - 18 - - 65 15 - 1.4 1.4 240 2.6 70 200 1 - - 1.9
Hungary
[30]
125 1 0.8 - 60 100 1 19 125 100 - 7.5 200 1.6 1.8 1,800 4 100 500 1 - - 2.6
Bangladesh
[24]
- - 0.4 - 60 - - - - - - - - - - - - - - - - - -
India [25] 240 - 4 - 120 - - 15 - - - 10 - 2.5 2.5 1,200 - 40 400 - - - 2
Cuba [36] - - 5 - - - - - - - - - - - - - - - - - - - -
Vietnam 1
[33]
- - 3.5 - 60 a - - - - - - - - - - - - - - - - - -
Netherlands
[37]
- - 0.4b
China 1 [34] - - 0.4 - - - - - - - - - - - - - - - - - - - -
China 2
[32, 35] c
100 2 0.4 - 10 30 3 14 77 4 30 10 100 1.4 1.4 169 3 60 200 8 - 4 -
Burkina Faso
[21]
- - 2.8 - 60 - - - - - - - - - - - - - - - - - -
Ireland [22] 480 - 0.36 - 50 - - 15 - - - - - 1.5 1.5 1,200 - 40 400 - - - 1
Algeria [38] - - - 240 - - - - - - - - - - - - - - - - - - -
Multi-
country
1 [23]
- - 4 - - - - 13 - - - - - 1.5 1.5 1,200 - 40 400 - - - 1
Multi-
country
2 [29]d
280 4 0.4 250 20 65 2.6 36 190 200 130 15 - 2.8 2.8 800 5.2 100 1,000 20 45 7 3.8
Vietnam 2 c
[26]
- 2 2.8 150 60 - - 18 - - 65 15 - 1.4 1.4 800 2 70 600 10 - - -
Nepal [28] - - - - - - - - - - - - - - - 7,000 - - - 5 - - -
aWeekly dose of 60 mg increased to 120 mg week when pregnant. Trial compared weekly with a daily dose of 60 mg iron and 250 μg folic acid
bFolic acid 0.4 or 0.5 mg and 15 % used as part of a multivitamin supplement regimen
cIn addition 100 μg molybdenum
dNutrient content in lipid-based supplement containing: 118 kcal energy, 2.6 g protein, 10 g fat, 4.59 g linoleic acid, 0.59 g α-linolenic acid
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defects in women with a previously affected infant
[20, 22, 23, 25, 36]. Different supplement multimicro-
nutrient content, dosages, and consumption patterns,
with or without food, could influence effects. Uni-
formity across future periconceptional trials would fa-
cilitate comparative analyses.
Table 4 summarises considerations related to the se-
lection of single or multimicronutrient interventions.
In principle, this decision should relate to a mechanis-
tic hypothesis, although in practice, holistic consider-
ations may be prioritised, such as a high population
prevalence of several micronutrient deficiencies. The
selection of control groups can be problematic. Trial
designs frequently use pregnant women who received
iron and folic acid supplements as controls, although
iron may be included in the composite supplement for
the intervention group. Ethically this meets inter-
national recommendations for the prevention of preg-
nancy anaemia, but concomitantly restricts the facility
to examine some nutrient-specific hypotheses. Supple-
ments given to control, or placebo groups varied
between those receiving two, three, five, or fewer
micronutrients [6, 30].
Cohort size and composition
Study sample size is governed by non-inferiority (or su-
periority) margins between trial arms, and estimates of
numbers lost to follow-up, migrations, withdrawals, and
deaths. These latter factors may be considerable for
studies undertaken in low resource settings. The propor-
tion of marriageable young women may affect the study
sample, as marriage generally involves movement to a
Table 4 Factors related to use of a single or multimicronutrient periconceptional supplements
Single nutrient supplementation Multimicronutrient supplementation
General points: General points:
(a) Potential negative interactions between multiple nutrients [107] (b)
Identification of the gestational timing of specific nutrient effects (c)
Allows specific hypotheses to be tested as single nutrient effects can be
identified, e.g., calcium supplementation and pre-eclampsia [108], or
folic acid and neural tube defects (d) Preferred for assessment of
dose–response associations (e) Facilitates safety and adverse outcome
assessments, e.g., infection risk with iron supplementation (NIH), or
folate use and cancer risk [109]
(a) Nutrient synergisms enhance potential benefits [110] (b) Theoretical
need for multiple nutrients from early in gestation, and for normal
placentation (c) Balanced supply of carbohydrates, lipids, proteins and
vitamins is critical to meet fetal and maternal energy needs, and for
substrates for metabolic pathways [104, 111] (d) Unlikely single nutrient
intervention will improve placental function, as combined deficiencies are
common in low resource settings, and combination of nutrients potentially
ameliorates several underlying nutrient deficiencies (e) Requirement for
ideal mixture of functional amino acids and micronutrients to regulate key
metabolic pathways [82] (f) Optimal nutrition from early in pregnancy may
help ameliorate need for advanced therapies of neonatal care in low
resource settings (g) Greater increase in body stores of nutrients than with
single nutrient supplementation
For iron: Specific multimicronutrient effects:
(a) Targets pre-existing iron deficiency anaemia and addresses need to
enter pregnancy with adequate iron stores [112] (b) Data from
experimental animals that iron status early in gestation may effect
auditory responsiveness [113] (c) Assessment of specific interactions
related to safety, e.g., iron-infection interactions influencing susceptibility
to infection [14]
(a) Vitamins B2, B6, B12, magnesium and iron combined with folic acid
may have greater protective effect in reducing risk of neural tube defects
[30, 35, 114] (b) Benefits in improving content of breast milk for several
nutrients [115] (c) Nutrient-nutrient synergisms may enhance iron
absorption [116] (d) Folate and other vitamins measured longitudinally
in pregnancy have values mostly below recommended levels [64], and
accelerated breakdown suggested in addition to haemodilution [117] (e)
Observational studies for less growth restriction and reduced pre-term birth
with regular periconceptional multivitamins [118] (f) Evidence for improved
birth weight with later gestational supplementation [8]
For folate:
(a) Specific maternal and fetal metabolic enzyme polymorphisms can be
targeted (e.g., methyl tetrahydrofolate reductase) [64] (b) Folate
requirements increase steeply once the chorioallantoic placenta is
formed and the fetal heart starts perfusion (about 22 days after
fertilisation) (c) Folate and vitamin B12 linked to utero-placental vascular
resistance [119]
For iodine:
(a) Mild to moderate iodine deficiency may influence cognitive
development [102]
Placental and genetic
(a) Specific nutrients may be involved in expression of genes involved
in placental function and cell cycle processes [120] (b) Identification of
factors controlling trophoblast turnover from immature to mature villi
Brackets: reference number
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new home. Exclusion of participants who indicate an
imminent change in residential location at enrolment is
sometimes adopted, but such movements are not always
predictable and the effect on loss to follow-up may be
substantial. If the primary outcome is a pregnancy vari-
able, and only a minority of the pre-pregnancy cohort
subsequently conceive, the protective effect of random-
isation against bias may be weakened.
A standard definition of fertility is the number of live
births per 1,000 women aged 15–49 years in a given year
(number of births per year/number of women 15–49
years). An estimate of the population fertility rate is es-
sential in order to estimate accrual of pregnancies, the
period of time to attain this, and the size of the residual
non-pregnant cohort. In practice accurate fertility esti-
mates are only available in areas where there has been a
recent census, or if the study is undertaken in a demo-
graphic surveillance area. Approximate fertility estimates
may be misleading and can jeopardise trial integrity if
the approximation substantially overestimates the true
rate.
As an example, Fig. 4 shows fertility rates, by five-year
age groups and birth order, for Moroccan women using
National Demographic Health Surveys (DHS) data [62].
Based on these fertility rates, parity and maternal age ef-
fects across groups would have an impact on cohort
study design, because age-specific fertility depends on
the proportion of the fertility distribution spent in each
category. An average fertility rate would be confounded
by residual parity and age effects. These may be consid-
erable over a long period of trial supplementation. Using
the DHS data plotted in Fig. 4, the estimated number of
births by differential age and parity fertility rates (parities
1, 2, and 3), and for increasing population sample sizes,
are shown in Table 5. This illustrates the substantial nu-
merical variation between class groups, emphasising the
importance of accurate demographic data for estimating
the sample size. This will be dictated by whether study
objectives relate to all parity groups or focus on a spe-
cific group such as nulliparae. An example was the
PALUFER periconceptional trial, in which malaria in
primigravidae early in pregnancy was the primary out-
come, as malaria affects more primigravidae than multi-
gravidae [21].
If the study allows recruitment across parities, prior
construction of a differential age-parity fertility rate table
will be helpful in estimating the sample size. This can be
done using DHS, recent census or local demographic
surveillance data, thus avoiding inaccurate approxima-
tions that may require extension of the enrolment
period. One periconceptional trial in this review was dis-
continued because of low fertility rates, combined with a
fall in occurrence of the primary outcome of neural tube
defects [22]. Secular declines in fertility, particularly in
Asia, may occur between censuses and need to be
allowed for. Sub-Saharan Africa is the only major region
in the developing world that has not yet undergone a
general decline in fertility.
Figure 5 shows the increase in the cohort sample size
of pregnant women, and proportional decrease for the
non-pregnant cohort, using data from Table 5. This is
plotted for six-monthly sequential supplementation pe-
riods for a total of 18 months supplementation, and
using an enrolment sample of 2,000 nulliparous women.
It highlights a number of points: with higher fertility
rates shorter periods of supplementation are required to
Fig. 4 Fertility rates by five-year age groups and birth order. Data is plotted from a Demographic Health Survey for Morocco for women of
child-bearing age. [Source: reference 62]
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reach an expected sample size; lower fertility requires
longer supplementation periods for non-pregnant
women; the non-pregnant cohort experiences longer
periods of supplement exposure than the pregnant
cohort for all fertility rates; if the duration of supple-
mentation is an important variable (for example, for
safety assessments, tolerability), then the sample size
should be estimated according to this variable; there are
programmatic implications, as the impact of different
durations of supplement delivery relate to the fertility
rate.
Outcome measurements
Assessment options will be dictated by study hypotheses,
although a broad-based approach to profiling outcomes
is useful. Table 6 summarises the range of parameters to
be considered for non-pregnant and pregnant cohorts,
for post-partum and infant assessments, and biochemical
markers relevant for placental studies. These are
grouped by categories related to study activities and po-
tentially relevant mechanistic hypotheses. Relevant spe-
cimen sampling is described which covers major
biological options to be considered. In view of epigenetic
phenomena and the potential associations between ma-
ternal micronutrient status and genetic variants in meta-
bolic enzymes affecting health, genotype profiling is
included [63]. The seminal example is reduced efficacy
of periconceptional folic acid supplementation with defi-
ciency of folate metabolising enzymes [64], but a much
broader approach assessing multiple enzyme loci is pos-
sible [65]. Ethical permission for collection and storage
of blood spots and sera should be anticipated if the
study aims do not relate to a primary genetic hypothesis,
as it would permit post hoc genotype profiling. This is
especially relevant if study protocols are complex, pro-
longed or costly, as repeat studies may not be feasible
and future studies would be potentially biased by time-
varying confounding.
Randomised trials are the best design for testing inter-
vention effectiveness, but more detailed laboratory sci-
ence is required to explore possible causal mechanisms
that can inform the development of interventions. Profil-
ing a wider biochemical range of nutrients with mater-
nal, neonatal and infant outcomes could help to identify
additional interventions. Advances in metabolomics now
make this possible [66], with screening of large sample
Table 5 Estimated annual numbers of births by differential age and parity (P1, P2, P3) fertility rates
Population
of women
of child-
bearing
age (n) a
15 – 19 yrs 20 – 24 yrs 25 – 29 yrs 30 – 34 yrs 35 – 40 yrs
Fertility rates Fertility rates Fertility rates Fertility rates Fertility rates
P1 P2 P3 P1 P2 P3 P1 P2 P3 P1 P2 P3 P1 P2 P3
54.6 23.5 8.2 76.2 75.4 53.0 37.2 52.7 64.8 15.0 24.5 34.5 3.2 5.8 14.8
1,000 55 24 8 76 75 53 37 53 65 15 24 35 3 6 15
2,000 110 48 16 152 150 106 74 106 130 30 48 70 6 12 30
3,000 165 72 24 228 225 159 111 159 195 45 72 105 9 18 45
4,000 220 96 32 304 300 212 148 212 260 60 120 140 12 24 60
5,000 275 120 40 380 375 265 185 265 325 75 144 175 15 30 75
aDemographic population size
Fig. 5 Interaction of duration of supplementation and fertility rates on cohort sizes. Hypothetical cohorts of pregnant and non-pregnant women
based on 2,000 nulliparous participants enrolled aged between 15–24 years, and fertility rates per 1,000 nulliparous women per year of 54.6
(15–19 years) and 78.2 (20–24 years). Fertility rates derived from Fig. 4
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Table 6 Assessment considerations in periconceptional supplementation trials
Study activity Non-pregnant Pregnant Placenta Post-partum Child (birth – 24 months)
Health history
and assessment
Exclusion criteriaa Demographic and
socio-economic status; Food security,
dietary and drug history; Morbidity, ob-
stetric and reproductive histories; BP;
mental health; workload
Uterine artery pulsatility (UtAPI) and resistance
indices (UtARI) at 28–32 w gestation;b BP;
Ultrasound: 1st trimester: gestational and yolk
sac development; 2nd/3rd: biparietal diameter,
HC, AC, FL; LMP; drug use
History of pre-eclampsia Mental health Gestational assessment, infant
feeding practices, neuro-
behavioural assessments, fat-
free mass oto-acoustic emis-
sions; drug use
Anthropometry
c
Wt, Ht, MUAC, Skin-fold thickness, BMI,
ultrasound of abdominal visceral fat
Wt, Ht, MUAC Wt, diameter Wt, Ht, MUAC, BMI Wt, recumbent Lt, crown-
rump Lt; head, upper arm, ab-
dominal circumference
Haematology Baseline anaemia Hb, MCHC, MCV, red cell distribution width Cord Hb, ferritin, sTfR Hb, cord clamping
time
Hb at 3, 6 12 months
Biochemistry Iron biomarkers,d sera and RBC folate,
micronutrient profiling, metabolome
Iron biomarkers, sera and RBC folate; amino
acids, lipids, fatty acids, renal function,
gluconeogenesis, anti-oxidant profile,e
metabolome
Ratio plasminogen-activator in-
hibitor (PAI)-1: PAI-2,f uterine-
artery Doppler waveform at 18–
22 weeks gestation,f cord blood
metabolitesg
Iron biomarkers,
micronutrients,
amino acids, lipids,
fatty acids, breast
milk composition
Iron and folate biomarkers,
amino acids, lipids, fatty acids,
micronutrients, anti-oxidant
profile,e metabolome
Endocrinology Adipose tissue-secreted hormones (adipo-
kines): leptin, visfatin, resistin, apelin,
omentin, sex steroids, growth factors
Cortisol, progesterone, oestradiol, thyroid
function, pregnancy associated plasma protein-
A (PAPP-A); free β-human chorionic gonado-
trophin (β-hCG)
Cord placental growth factor
(PlGF); soluble FMS-like tyrosine
kinase-1 (sFlt1)h
Adipokines Hormonal growth factors,
glucose homeostasis
Infection Blood/stool samples, STIsi HIV, bacterial
vaginosis, vaginal microbiome
Bacterial vaginosis, STIs Chorioamnionitis, malaria
histology
Bacterial vaginosis,
vaginal microbiome
Gut helminths, malaria,
respiratory, diarrhoea, HIV,
health attendances, fecal
microbiome, thymic size
Inflammation CRP, AGP CRP, AGP Specific maternal-cord antibody
titres
CRP, AGP CRP, AGP
Genotype
profile
Blood storage - Micro RNAsj - Blood storage, micro RNAs
Abbreviations: Wt weight, Ht height, MUAC mid-upper arm circumference, BMI body mass index, HC head circumference, AC abdominal circumference, FL femur length, CRP serum C-reactive protein, AGP alpha-1-acid
glycoprotein, Hb haemoglobin, BP blood pressure, STI sexually transmitted infections, LMP last menstrual period
a Dependent on study design and location these would include: sickle cell disease and hemoglobinopathies; severe anaemia (Hb <7 g/dl); diabetes; current pregnancy; pre-menarcheal subjects; severe malnutrition or
other severe illness (see study design section)
b The uterine artery pulsatility index (UtAPI) and resistance index (UtARI) at 28–32 weeks gestation and record of diastolic notching. Quantify systolic and diastolic components of the flow velocity waveform in a
specific blood vessel over a single cardiac cycle, with higher values indicating downstream vascular resistance
c Duplicate measurements
d Serum ferritin, transferrin receptor (sTfR), hepcidin, free erythrocyte protoporphyrin, transferrin saturation
e Metabolomic profiling
f A surrogate marker of placental perfusion which correlates with trophoblast invasion [15]
g Blood metabolites including: insulin, glucose, liver enzymes, amino acids, fatty acids
h Placental growth factor (PlGF) is a proangiogenic factor sharing high homology with vascular endothelial growth factor; soluble FMS-like tyrosine kinase-1 (sFlt1) is a potent antagonist of vascular endothelial growth
factor and PlGF signalling
i Screening for regionally specific infections; parasitic infections (e.g., malaria, enteric helminthiasis, schistosomiasis); genital tract infections (e.g., bacterial vaginosis, STI syndromes)
j Placental micro RNA expression of small non-coding RNAs that are involved in post-transcriptional gene regulation
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numbers using mass spectrometry or nuclear magnetic
resonance spectroscopy. Novel biomarkers may be
assessed for predictive accuracy for fetal growth restric-
tion and other pregnancy outcomes [67, 68]. For these
reasons a storage sera set should be secured for future
examination, and potentially to allow cross-cohort com-
parisons for replication across studies and use of tri-
angulation methods [17].
Some of the general profiling options outlined in
Table 6 may not be measured for pragmatic reasons, or
because they do not relate to study objectives. In order
to illustrate a specific trial outline, Table 7 shows the ac-
tivities for the PALUFER trial of malaria risk prior to
and during early pregnancy in nulliparous women re-
ceiving long-term weekly iron and folic acid supplemen-
tation [21]. This was a non-inferiority randomised
controlled trial based on infection risk parameters,
where the primary endpoint was malaria infection at the
first scheduled antenatal visit. Malaria prevalence in the
non-pregnant cohort was also assessed at an end assess-
ment survey. The study used the structure outlined in
Fig. 3, which provided a platform for a series of second-
ary analyses, for pregnant and non-pregnant cohorts.
Risk of bacterial vaginosis, a major risk factor for chor-
ioamnionitis, was also assessed in both cohorts [69]. De-
tailed baseline profiling allowed the predictive value of
biomarkers to be assessed for subsequent health out-
comes. The large size of the residual non-pregnant co-
hort provided adequate statistical power for secondary
outcome assessments. In the PALUFER trial, partici-
pants were consented at enrolment, re-consented at first
antenatal visit, and again for the infant cross-sectional
survey, and this included permission for sample storage.
Adherence assessment
Assessment of adherence to supplementation in the
periconceptional trials shown in Fig. 2 was generally by
tablet counts, and reported as the percentage compli-
ance. This is probably not sufficient, as percentage com-
pliance obtained by counting tablets can be calculated in
different ways. Trial details are shown in Table 8 with
assessment frequency varying from weekly to every three
months. One of these trials reported an outcome assess-
ment (change in haemoglobin) by quartiles of percent
adherence [24]. The epidemiology of supplement intake
patterns requires better description than total tablet
counts, and current trials should be able to provide a
more detailed analysis of the potential influence of ad-
herence patterns on study outcomes [21]. With longer
supplementation adherence may be discontiguous, with
intake discontinued and re-commenced for variable
monthly periods, resulting in intermittent patterns and
variable adherence exposure at the time of conception,
especially as seasonal factors may be influential.
Percentage compliance does not capture this variation,
as in longitudinal trials adherence is a rate rather than a
period prevalence, and would be more precisely
expressed as a rate in person weeks/months of follow-
up. One study used directly observed intake [21], which
is a definitive method of assessment, but even this does
not secure intake if participants are absent for variable
periods. Trials need to be adequately powered to allow
for this influence, in particular with long periods of
supplementation.
The adherence level is one criterion used to distinguish
per protocol from intention-to-treat populations. Of the
studies outlined in Fig. 2, all used an intention-to-treat
analysis approach without attempting to define a theoret-
ical per protocol population. This definition would require
a percentage compliance cut-off, or particular compliance
profiles to be selected, the biological basis of which may
be uncertain. This is particularly challenging where partic-
ipants have highly variable uptake patterns and excellent
adherence is impossible to achieve. With improved bio-
chemical measures of exposure it may be possible to de-
velop alternative assessment methods.
There are reasons to believe that adherence to medica-
tion may differ between arms, for example, if side effects
varied by trial arm, or if the control group knew they
were taking placebo, and so would not be independent
of randomisation. Strata generated by adherence may
therefore compare dissimilar patients from each treat-
ment arm. There are therefore some problems in inter-
preting analyses that include a stratified adherence
variable. It is nevertheless important to describe the level
of adherence by treatment arm in a non-inferiority trial,
as non-adherence results in a bias towards the alterna-
tive hypothesis. With non-compliance in the interven-
tion arm, an adherence-based analysis may provide
meaningful information (causal effect estimate of the
treatment effect) [70]. The effect of non-adherence
should be considered in secondary analyses.
The role of qualitative studies
Only one trial in Burkina Faso included a qualitative
component [21], in which focus group discussions with
non-trial participants and field workers were conducted
early in the study before supplementation had been
established. The data drew attention to misconceptions
about the purpose of supplementing unmarried, non-
pregnant women in a setting in a developing country,
which the team tried to address in subsequent community
contacts (71). A high level of illiteracy in the rural study
area compounded such misconceptions. Detailed inter-
views with participants who had varying levels of supple-
ment adherence were also conducted at later stages, giving
insights into unexpected factors that interfered with regu-
lar adherence and loss to follow-up, some of which could
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be addressed by the field team. Qualitative studies con-
ducted in parallel with the main trial could assist in
informing trial management, but may only be able to ad-
dress a limited number of potential problems, especially in
rural, more isolated communities in low resource settings.
Examples include: falling adherence with longer supple-
mentation periods; hidden pregnancies or abortions; ado-
lescent pregnancies in unmarried women; miscarriages
which may be interpreted as irregular menstruation, and
their distinction from false positive pregnancy tests; misin-
formation on the nature of the intervention [71] or
confusion with contraception; insufficient communication
with local communities and partners or husbands. Some
trials have enrolled only married participants, which may
reduce occurrence of some of these factors, although in
areas where unmarried adolescent pregnancy is common,
this may result in selection bias. Protocol amendments
may be required to address specific factors in order to en-
sure optimal trial participation, participant security, and
community compliance. The Gambia trial did not integrate
a qualitative component because it was a mechanistic study
and also to avoid raising concerns about the nutritional
Table 7 Profile of PALUFER trial activities evaluating weekly iron supplementation [21]
Study contact Health history and assessment Haematology Biochemistry Anthropometry Infection and inflammation screena
Screening Demographicsb - - - -
Randomisation Reproductive,c general health,
blood pressure, temperature,
dietary,e drugs
Sera for iron
biomarkers,d
Hb if pallor or
symptomatic
Blood for
sera and
genotype
Wt, Ht, BMI,
MUAC
Malaria if symptomatic, vaginal,
STI (syndromic)
Non-pregnant
cohort
- Weekly visitsf T0 C and morbidity,g side effects,
compliance,
- - - RDT for malaria if symptoms/febrile
- Cross-sectional survey T0 C and morbidity, side effects - - - All for malaria microscopy
- Participant
unscheduled visits
T0 C and morbidity, side effects - - - If symptoms
- End assessment survey T0 C and morbidity, side effects Hb, iron
biomarkers
Nutritional
biomarkersh
Wt, Ht, MUAC Malaria RDT and microscopy, BV,
CRP, vaginal microbiome and
lactoferrin, trichomonas
-Focus groups/
interviews
Knowledge and acceptability - - - -
Pregnant cohort
- First AN attendance i
at 13–16 wks
T0 C and morbidity, ultrasound,
blood pressure, drugs (IPTp),
supplement, compliance, side
effects
Hb, iron and
folate biomarkers
Urine
glucose
and protein
Wt, Ht, MUAC Malaria RDT and microscopy, CRP
and AGP, BV, HIV, STI (syndromic),
vaginal lactoferrin and microbiome,
trichomonas
- Second AN
attendance at
32–36 wks
T0 C and morbidity, blood pressure,
drugs (IPTp)
Hb if pallor or
symptomatic
Urine
glucose
and protein
Wt, Ht Vaginal lactoferrin and microbiome,
other infections if symptoms
- Unscheduled visits T0 C and morbidity Hb if pallor or
symptomatic
- Wt Other infections if symptoms
- Delivery T0 C and morbidity, stillbirths - - Wt Placental histology for
chorioamnionitis and malaria
Infant follow-up
-Live births Gestational age - - Wt, length, HC -
-Cross-sectional
postnatal survey
Infant feeding, morbidity,
health visits
Hb, iron
biomarkers
- Wt, length,
MUAC
Malaria
Abbreviations: Ht height, Wt weight, HC head circumference, BMI body mass index, MUAC mid-uper arm circumference, T0 temperature, BV bacterial vaginosis, STI
sexually transmitted infection, IPTp intermittent preventive treatment for malaria (sulfadoxine-pyrimethamine), HIV human immunodeficiency virus, CRP C-reactive
protein, AGP acyl glycol-protein, Hb haemoglobin, RDT rapid diagnostic test for malaria
a Malaria, or other exposures, e.g., vaginal infections including bacterial vaginosis and trichomonas, HIV infection
b Location, marital status, occupation, education, ethnicity, likelihood of migration, socio-economic status
c History of menarche, sexual history, previous pregnancies, live births, stillbirths, sickle cell disease
d Serum ferritin, transferrin receptor, hepcidin, free erythrocyte protoporphyrin, mean corpuscular Hb concentration (MCHC), red cell distribution width
e Including use of nutrition supplements
f Variable frequency dependent on study requirements (weekly supplements for PALUFER trial)
g Questions related to fever, respiratory and gastro-intestinal symptoms, skin rashes, or since previous visit. Includes mortality record
h Sera for vitamin and micronutrient concentrations
i Gestational timing and frequency dependent on study objectives
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Table 8 Supplement compliance and uptake for studies outlined in Fig. 2
Trial location
(reference)
Double
blind
Tablet
regimen
Supplement duration Adherence
assessment
method
Side effects
monitored
Adherence
Wales [20] Yes Daily Not reported a Serum folate
cut-off
Yes 73 % Not assessed in
controls
Gambia [27, 31] Yes Daily Mean 10.9 weeks pre-conception
to 11 weeks post-conception
Two weekly
home tablet
counts
Yes 88 %.
Median 24.1 weeks Supplement clinic
attendance 72 %
Hungary [30] No Daily Up to 9 months pre-conception
to 3 months gestation
Three monthly
tablet counts
Yes 71.5 % full course
8.9 % no supplementsb
19.6 % partial
supplementsc
Bangladesh [24] Yes Daily Maximum 9 months Monthly sachet
counts
Yes 57.7 ± 26.9 %d
Mean 72.9 days
India [25] Yes Daily ≥1 month pre-conception – 3
months post-conception
Three monthly
tablet counts
Yes 34 % lost to follow-up
before conception
Cuba [36] No Daily One menstrual period before
conception − 10 weeks gestation
Not reported No 19.8 % partial
supplementsc
55.1 % no supplementsb
Vietnam 1 [33] No Weekly
vs daily
Up to 9 months Tablet purchases No? 50-92.5 %, variable with
period of follow-up
Netherlands
[37]
No Daily Not reported Self-reported No? 29.6 % reported not using
China 1 [34] No Daily Maximum 38 months Monthly bottle
counts
No 81–87 %
periconceptionale
74–75 % late usef
68–78 % discontinuedg
China 2 [32, 35] No Daily At least 3 months pre-conception.
Mean 149.8 days pre- and 49.3 days
post-conception
Monthly capsule
counts
No 85.7 % – 93 % compliance
Burkina Faso
[21]
Yes Weekly Maximum 18 months Directly observed
intake
Yes Trial in progress
Ireland [22] Yes Daily At least 2 months pre-conception Tablet counts
and blood testsh
Yes Not reported
Algeria [38] No Single
dosage
Either 1–3 months pre-conception,
or 1–3 months gestation
Directly observed Not applicable 100 %i
Multi-country
1 [23]
Yes Daily Continuous until 12th week
gestation
Three monthly
capsule counts
Yes 7 % discontinued;g 3–8 %
took 50–79 %; 0.8 %
took <50 %
Multi-country
2 [29]
No Daily Not reported Self-reported
sachet use
Yes Trial in progress
Vietnam 2 [26] Yes Daily Maximum 18 months Two weekly
capsule counts
Yes Trial in progress
Nepal [28] Yes Weekly ≤3.5 years Directly observed No? >75 % pregnant≥ 50 %
62 % non-pregnant ≥
50 %
aFrom time contraception stopped
bZero adherence
cIncomplete adherence
dPercentage total eligible doses consumed
eStarted supplement before last menstrual period before conception and stopped at end of first trimester
fStarted supplement during first trimester but after last menstrual period
gStarted and stopped supplement before last menstrual period before conception
hCount frequency not reported
iAssuming no refusals
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supplement [72], and this restricted its ability to manage
emerging issues. A study among non-participants illus-
trated extreme reluctance by women to disclose pregnancy
in the first trimester.
The role of qualitative studies within trials has been di-
minished by views that such studies are relevant only for
programmes, given that trials try to maximise adherence
by intensive supervision and benefits (such as treatment
and travel costs) that are not available routinely. Indeed, a
community mobilisation and social marketing study to
promote weekly pre-pregnancy iron and folic acid supple-
mentation to married, nulliparous women in Vietnam re-
ported that the purchase of supplements over four
months fell from 92.5 % to 67.4 % [33]. In Burkina Faso
the qualitative research has clearly shown that young
women see little benefit from taking supplements and
without free treatment, adherence would be much lower
[21]. It would be better to anticipate such problems rather
than have to initiate new studies to promote uptake fol-
lowing policy recommendations for supplementation.
Data management
The data management of periconceptional trials can in-
corporate three categories of participants: non-pregnant,
pregnant, and child cohorts, as well as longitudinal and
cross-sectional data sets. All data can be handled in an
electronic case record form (CRF) developed in MACRO
(Infermed©). This is a powerful, industry-standard elec-
tronic data capture solution, which supports trials from
Phase I through IV. It is designed to increase compliance
with the requirements of relevant regulatory bodies in-
cluding the International Conference on Harmonisation
(ICH) Good Clinical Practice, and Federal Drug
Administration-CFR21Part11 compliance. It also allows
exchange of an entire clinical study between two differ-
ent and independent study software solutions, facilitat-
ing exchange of metadata [73]. Considering the sample
size and the long weekly follow-up period, source data
collection of the weekly household visits using hand-
held portable devices is preferable to facilitate real-time
data validation, to avoid duplicate data entry, and to sim-
plify batch data entry of large inter-related data sets.
The complexity of work flow with periconceptional tri-
als requires an ability to effectively track participant
compliance with complex protocol schemas (such as
intervention schedules, data collection requirements,
parallel cohort tracking, monitoring of side effects, se-
quential delivery times and participant recruitment, and
participant out migration) [74]. Participant attrition as a
result of protocol noncompliance can result in increased
costs, delayed completion times, biased data, and ambi-
guity over protocol violations. Validated methods for
clinical trial participant tracking are required [75], which
will enhance data safety and monitoring reporting.
Conclusions
There are many challenges facing early-life intervention
studies, and trials in developing countries will have op-
erational requirements which are context specific, and
likely to be dependent on the literacy rate in the study
population. This review has focussed on pragmatic issues
that we hope can be drawn upon and expanded as experi-
ence grows with more completed studies. Periconceptional
trials are distinguishable from pregnancy supplementation
trials, not only because of the early gestational timing of
nutrient exposure, but also because they generate a subsid-
iary trial in participants who remain non-pregnant. This
provides an opportunity to evaluate concurrent hypotheses
related to the health of women who may become pregnant.
An expanded framework for conceptualisation, design, and
implementation is required in order to reduce risks in
achieving outputs, strengthen trial integrity, facilitate repli-
cation and data exchange and reduce costs. Basing trial
design on a mechanistic hypothesis is an important pre-
requisite which relates to the choice of a single or multiple
micronutrient intervention. Micronutrient interventions
are relevant across the entirety of a women’s reproductive
period, even more so in young nulliparae and grand mul-
tiparae [76]. Longitudinal reference values for biochemical
markers are required in uncomplicated pregnancies to fa-
cilitate interpretation [77]. Iron would be a requirement of
most periconceptional supplements, especially in develop-
ing countries, as many women enter pregnancy with inad-
equate iron stores [78]. Early pregnancy iron deficiency has
been associated with poorer [79], and iron supplementa-
tion with better birth weight outcomes [80, 81], although
questions remain concerning iron-infection interactions
which may have an impact on safety under specific infec-
tion exposures [14]. Folate is a requirement in view of
strong evidence for periconceptional use preventing neural
tube defects. The rationale for multimicronutrient dosage
and content needs to be clearly outlined, in order to estab-
lish a comparative framework, improve standardisation,
and facilitate interpretation of mechanistic hypotheses.
Other issues identified include: rationalisation of the
duration of supplementation; problems with excluding
anaemic participants at baseline; influence of follow-up
intensity on intervention adherence; and out-migration,
particularly in adolescent cohorts. Research and practice
recommendations include: utilising accurate fertility data
for both sample size and supplement duration estima-
tions; prioritising placental tissue sampling; establishing
appropriate safety assessments incorporating infection
risk; inclusion of an infant follow-up; utilisation of elec-
tronic case record forms on MACRO (Infermed); and
qualitative concurrent assessments prior to and during
trial implementation. Qualitative assessments are not
solely theoretical, as trial results will not appeal to policy
makers if they are not implementable. This is a
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particular issue with pre-pregnancy studies and in first
pregnancies, as women unfamiliar with routine care may
fail to comply with supplementation. This may re-direct
efforts towards food fortification, which are less realistic
in some low resource settings. With more comprehen-
sive assessments the complexity of the work flow and
processes executed by the field clinical investigator
should not be underestimated.
The heterogeneity of studies included in this review,
which covers both randomised trials and prospective co-
hort studies, limited comparability. There was a predom-
inance of studies examining NTD outcomes following
folate supplementation, and considerable variation in
duration of supplementation across studies. These differ-
ences related partly to assessment of alternative study
outcomes, but most were not rationalised in physio-
logical terms. While this lack of uniformity limited com-
parability, it facilitated identification of methodological
issues relevant to future trial conduct.
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